CG Oncology Inc. Common s... (CGON)
NASDAQ: CGON
· Real-Time Price · USD
25.77
-0.19 (-0.73%)
At close: Aug 15, 2025, 10:18 AM
-0.73% (1D)
| Bid | 25.73 |
| Market Cap | 1.97B |
| Revenue (ttm) | 662K |
| Net Income (ttm) | -105.56M |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | -14.48 |
| Forward PE | -13.83 |
| Analyst | Buy |
| Ask | 25.9 |
| Volume | 53,725 |
| Avg. Volume (20D) | 881,598 |
| Open | 26.10 |
| Previous Close | 25.96 |
| Day's Range | 25.65 - 26.14 |
| 52-Week Range | 14.80 - 40.47 |
| Beta | 0.88 |
About CGON
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CGON
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CGON stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
CG Oncology Inc. Common stock is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+4.72%
CG Oncology shares are trading higher after JP Mor...
Unlock content with
Pro Subscription
3 months ago
+25.03%
CG Oncology shares are trading higher after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.
6 days ago · fool.com
Cg Oncology (CGON) Q2 Loss Widens 93%Cg Oncology (CGON) Q2 Loss Widens 93%
1 month ago · seekingalpha.com
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash p...
